Citadel Advisors LLC purchased a new position in Anteris Technologies Global Corp (NASDAQ:AVR - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 207,920 shares of the company's stock, valued at approximately $1,160,000. Citadel Advisors LLC owned 0.58% of Anteris Technologies Global at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in AVR. Nantahala Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $9,300,000. Regal Partners Ltd purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $7,220,000. ADAR1 Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $5,876,000. Altium Capital Management LLC purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $4,112,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Anteris Technologies Global during the 4th quarter worth approximately $3,069,000.
Anteris Technologies Global Price Performance
Shares of AVR traded down $0.15 during mid-day trading on Friday, hitting $4.36. 156,673 shares of the stock were exchanged, compared to its average volume of 205,328. The stock has a 50-day simple moving average of $3.86. Anteris Technologies Global Corp has a 52-week low of $2.34 and a 52-week high of $8.79.
Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.61) earnings per share for the quarter. On average, sell-side analysts expect that Anteris Technologies Global Corp will post -2.66 earnings per share for the current year.
About Anteris Technologies Global
(
Free Report)
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Featured Articles
Before you consider Anteris Technologies Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anteris Technologies Global wasn't on the list.
While Anteris Technologies Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
